Nektar Therapeutics ((NKTR)), Nektar Therapeutics (($CC:NKTR.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The recent clinical study update from Nektar Therapeutics focuses on a Phase 2b trial titled ‘A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis.’ The study aims to assess the efficacy and safety of Rezpegaldesleukin, a pegylated-recombinant-human interleukin-2, in treating moderate-to-severe atopic dermatitis. This study is significant as it explores a potential new treatment option for a condition that affects a significant portion of the population.
The intervention being tested is Rezpegaldesleukin, administered as a subcutaneous injection. It is designed to modulate the immune system to reduce the symptoms of atopic dermatitis.
The study design is interventional and randomized, with a parallel-group model. It involves a double-blind approach, meaning neither participants nor the care providers know who receives the treatment or placebo. The primary purpose of the study is treatment-focused.
The study began on November 15, 2023, with an estimated completion timeline extending up to 104 weeks, including various phases such as screening, induction, maintenance, and follow-up. The last update was submitted on June 25, 2025, indicating ongoing progress.
This update could influence Nektar Therapeutics’ stock performance positively if the results show promise, as it would enhance their portfolio with a new treatment option. It may also impact investor sentiment favorably, considering the competitive landscape in dermatological treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.